Corbus Pharmaceuticals to Present CRB-701 Data at ASCO 2026, Host KOL Event
Event summary
- Corbus Pharmaceuticals will host an in-person and virtual KOL event at ASCO 2026 on June 1st to discuss updated Phase 1/2 data for CRB-701 in 75 HNSCC patients.
- Data includes clinical response durability and HNSCC patient subgroup analysis, to be presented as a poster at the ASCO annual meeting.
- The ongoing Phase 1/2 study has evaluated CRB-701 in 317 participants with advanced solid tumors associated with high Nectin-4 expression.
- Corbus recently announced broad alignment with the FDA on the registration path for CRB-701 in HNSCC.
The big picture
Corbus Pharmaceuticals' KOL event at ASCO 2026 underscores the strategic importance of CRB-701 in the oncology space, particularly for HNSCC. The company's alignment with the FDA on the registration path suggests a streamlined regulatory process, which could accelerate market entry. The event also highlights the growing emphasis on targeted therapies in oncology, with CRB-701's Nectin-4 targeting mechanism positioning it as a potential key player in the ADC market.
What we're watching
- Clinical Efficacy
- How the updated Phase 1/2 data for CRB-701 will impact its regulatory path and market potential in HNSCC.
- Regulatory Progress
- Whether the FDA alignment on the registration path for CRB-701 will accelerate approval timelines.
- Market Positioning
- The pace at which Corbus can differentiate CRB-701 in the competitive ADC market.
Related topics